Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

More data are needed on its efficacy and safety in treating relapsing multiple sclerosis. In two phase ... Supported by Sanofi. Disclosure forms provided by the authors are available with the ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

Throughout the course of multiple sclerosis, gradually progressive neurologic ... full text of this article at NEJM.org. Supported by Sanofi. Disclosure forms provided by the authors are available ...

Hoffman-LaRoche, Novartis, and Sanofi. Source Reference: Oh J, et al "Tolebrutinib versus teriflunomide in relapsing multiple sclerosis" N Engl J Med 2025; DOI: 10.1056/NEJMoa2415985.

About multiple sclerosis Multiple sclerosis is a chronic ... Tolebrutinib represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...